Plan ahead.
Help protect yourself, get vaccinated.
what-is-ticovac-banner
Plan ahead.
​​​​​​​Help protect yourself,
​​​​​​​get vaccinated.
Read About TicoVac & How It Can Help Protect You While Traveling
What is TicoVacTM?
If you’re heading to Europe or Asia, TicoVacTM is one way to help protect yourself against Tick-Borne Encephalitis.1-3 More than 45 years of experience with TicoVacTM exists outside the US.4
TicoVacTM is an FDA-approved vaccine indicated for the prevention of Tick-Borne Encephalitis (TBE) virus for people 1 year of age and older.1
TicoVac may help protect against the main TBE 
​​​​​​​virus subtypes found in nature5
Tick diseases are on the rise.3 Three main subtypes of TBE exist across Europe and Asia: European, Siberian, and Far Eastern.3 It’s difficult to know which TBE subtype you may come into contact with, so vaccination to help protect against known subtypes is important.
​​​​​​
​​​​​​Travelers are recommended to complete the primary TicoVac Immunization Series at least 7 days prior to potential exposure.1
​​​​​​​
96-99%
TicoVac™ has demonstrated field effectiveness in real-world studies.6-9
More about TicoVacTM
TicoVacTM has demonstrated real-world effectiveness against TBE.6-9 The vaccine has been in use for over 45 years.4
Check out the CDC guidance for TBE virus prevention.

VISIT THE CDC TO LEARN MORE

Even if you take every precaution to avoid a bite, ticks can be a crafty bunch. If any of the following are true regarding your travel plans, you may want to consider vaccination.​​​​​​​
Globe
Do you travel to, or are you planning to travel to Europe or Asia?
Calendar
Are you planning to travel between the months of April and November?
Travel
Will you spend time outdoors sightseeing, in a park, playing golf, hiking, camping, biking, etc., where it’s possible you could enter grassy areas?
Time
Is it possible you may participate in unplanned outdoor activities/excursions?
If you answered yes to any of the above, you should consult a Healthcare Provider or Pharmacist for vaccine information.
References
  1. TicoVac™ (Tick-Borne Encephalitis Vaccine). Prescribing Information. New York, NY: Pfizer Inc. 2021.
  2. Fischer M, Gould CV, Rollin PE. Tickborne Encephalitis. Centers for Disease Control and Prevention. CDC Yellow Book 2020: Health
    Information for International Travel
    . New York: Oxford University Press; 2017. Chap 4. Accessed February 24, 2022. https://
    wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/tickborne-encephalitis
    .
  3. Dobler G, Erber W, Bröker M, Schmitt HJ, eds. The TBE Book. 4th ed. Global Health Press; 2021.
  4. Barrett PN, Schober-Bendixen S, Ehrlich HJ. History of TBE vaccines. Vaccine. 2003;21 (suppl 1):S41-S49. doi:10.1016/
    s0264-410x(02)00814-9.
  5. Orlinger KK, Hofmeister Y, Fritz R, et al. A tick-borne encephalitis virus vaccine based on the European prototype strain induces
    broadly reactive cross-neutralizing antibodies in humans. J Infect Dis. 2011;203(11):1556-1564. doi:10.1093/infdis/jir122.
  6. Heinz FX, Stiasny K, Holzmann H, et al. Vaccination and tick-borne encephalitis, central Europe. Emerg Infect Dis. 2013;19(1):69-76.
    doi:10.3201/eid1901.120458.
  7. Heinz FX, Holzmann H, Essl A, Kundi M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine.
    2007;25(43):7559-7567. doi:10.1016/j.vaccine.2007.08.024.
  8. Pugh SJ, Moïsi JC, Kundi M, et al. Effectiveness of two doses of tick-borne encephalitis (TBE) vaccine. J Travel Med.
    2022;taab193:1-3. doi:10.1093/jtm/taab193.
  9. Erber W, Khan F, Zavadska D, et al. Effectiveness of TBE vaccination in southern Germany and Latvia. Vaccine. 2022;40(5):819-825.doi:10.1016/j.vaccine.2021.12.028.

IMPORTANT SAFETY INFORMATION AND INDICATION

Important Safety Information
  • TicoVac™ should not be given to anyone with a history of a severe allergic reaction after a previous dose of TicoVac™. 
  • TicoVac™ may not protect all individuals against TBE.
  • Some individuals with weakened immune systems may have a reduced immune response.
  • TicoVac™ contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.
  • The most common adverse reactions in subjects 1 through 15 years of age who received TicoVac™ were local tenderness, local pain, headache, fever, and restlessness.
  • The most common adverse reactions in subjects 16 through 65 years of age who received TicoVac™ were local tenderness, local pain, fatigue, headache, and muscle pain.
  • Tell your healthcare provider if you are pregnant, or plan to become pregnant.
  • Ask your healthcare provider about the risks and benefits for TicoVac™. Only a healthcare provider can decide if TicoVac™ is right for you.
Indication

TicoVac™ is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

IMPORTANT SAFETY INFORMATION AND INDICATION

Important Safety Information
  • TicoVac™ should not be given to anyone with a history of a severe allergic reaction after a previous dose of TicoVac™. 
  • TicoVac™ may not protect all individuals against TBE.
  • Some individuals with weakened immune systems may have a reduced immune response.
  • TicoVac™ contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases.
  • The most common adverse reactions in subjects 1 through 15 years of age who received TicoVac™ were local tenderness, local pain, headache, fever, and restlessness.
  • The most common adverse reactions in subjects 16 through 65 years of age who received TicoVac™ were local tenderness, local pain, fatigue, headache, and muscle pain.
  • Tell your healthcare provider if you are pregnant, or plan to become pregnant.
  • Ask your healthcare provider about the risks and benefits for TicoVac™. Only a healthcare provider can decide if TicoVac™ is right for you.
Indication

TicoVac™ is a vaccine indicated for active immunization to prevent tick-borne encephalitis (TBE) and is approved for use in individuals 1 year of age and older.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

Patients should always ask their healthcare providers for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit http://www.vaers.hhs.gov or call 1-800-822-7967.

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries.

The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

  • © 2022 Pfizer Inc.
  • All rights reserved.
  • Pfizer Inc. PO Box 29387, Mission, KS 66201
  • May 2022
  • PP-TCV-USA-0043
  • PP-TCV-USA-0043
  • PP-TCV-USA-0043